FDA To Rescind A 510(k): Rare Action Targets ReGen's Menaflex Device
This article was originally published in The Pink Sheet Daily
The formal rescission process, including the option for ReGen to request a regulatory hearing, will proceed after FDA staffers have met with the manufacturer to discuss an appropriate marketing pathway for the device.
You may also be interested in...
FDA will announce the outcome of its re-review of ReGen Biologic's 510(k)-cleared Menaflex knee repair device "in the coming weeks," CDRH Director Jeffrey Shuren said last week
An internal evaluation of FDA's handling of the controversial 510(k) clearance of a knee implant unearthed serious shortcomings in the integrity of the agency's review process, FDA said Sept. 24
Details trickling into the public sphere about CDRH's device review process reveal heightened tension between reviewers and management over the proper response to a 510(k) submission